GlassScriptPhysician profile
Jamie L Modaffari
NPI 1467729145
$2,135.70
in general payments reported to CMS, 2019-2025
19 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $96.86 · 2023: $146 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,764.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $619.20 | 2025 | Cequr Simplicity |
| Novo Nordisk INC | $582.01 | 2021-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $198.48 | 2023-2025 | |
| Beta Bionics, INC. | $186.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Janssen Pharmaceuticals, INC | $86.89 | 2021 | |
| Lilly USA, LLC | $65.61 | 2025 | Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $61.06 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $49.95 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.92 | 2025 | Jardiance |
| Amgen INC. | $47.94 | 2025 | Tepezza, Prolia, Evenity |
| Neurocrine Biosciences, INC. | $39.63 | 2025 | |
| Madrigal Pharmaceuticals | $21.83 | 2025 | Rezdiffra |
| Amneal Pharmaceuticals LLC | $21.41 | 2025 | Unithroid |
| Insulet Corporation | $19.97 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.37 | 2025 | Freestyle Libre 3 |
| Alvogen INC | $17.16 | 2025 | Teriparatide |
| Sequel Med Tech, LLC | $16.75 | 2025 | Twiist |
| Abbvie INC. | $14.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Modaffari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.